Edition:
United States

Spectranetics Corp (SPNC.OQ)

SPNC.OQ on NASDAQ Stock Exchange Global Select Market

27.20USD
25 May 2017
Change (% chg)

-- (--)
Prev Close
$27.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
76,870
52-wk High
$30.10
52-wk Low
$16.84

Latest Key Developments (Source: Significant Developments)

Spectranetics reports Q1 loss per share $0.43
Thursday, 27 Apr 2017 04:01pm EDT 

April 27 (Reuters) - Spectranetics Corp :Spectranetics reports first quarter 2017 revenue of $69.7 million.Q1 revenue rose 11 percent to $69.7 million.Q1 loss per share $0.43.Q1 earnings per share view $-0.34, revenue view $68.2 million -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $293 million to $306 million.Sees FY 2017 loss per share $1.31 to $1.43.FY 2017 earnings per share view $-1.18, revenue view $300.1 million -- Thomson Reuters I/B/E/S.  Full Article

Spectranetics reports Q4 loss per share $0.29
Thursday, 23 Feb 2017 04:01pm EST 

Spectranetics Corp : Spectranetics reports fourth quarter 2016 revenue of $71.9 million . Q4 non-gaap loss per share $0.21 . Q4 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S . Sees FY 2017 loss per share $1.31 to $1.43 . Q4 loss per share $0.29 . Sees fy 2017 revenue $293 million to $306 million . Q4 revenue $71.9 million versus i/b/e/s view $70.1 million .FY2017 earnings per share view $-0.88, revenue view $295.6 million -- Thomson Reuters I/B/E/S.  Full Article

Franklin Resources reports a 6 percent passive stake in Spectranetics as of Dec 31, 2016
Tuesday, 7 Feb 2017 02:05pm EST 

Franklin Resources, Inc :Franklin Resources reports a 6 percent passive stake in Spectranetics Corp as of December 31, 2016 -SEC filing.  Full Article

Spectranetics Q3 loss per share $0.31
Thursday, 27 Oct 2016 04:01pm EDT 

Spectranetics Corp : Spectranetics reports third quarter 2016 revenue of $68.3 million . Q3 loss per share $0.31 . Q3 revenue $68.3 million versus i/b/e/s view $65.8 million . Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Sees FY 2016 non-gaap loss per share $1.06 to $1.13 . Sees FY 2016 loss per share $1.40 to $1.47 . Sees FY 2016 revenue $265 million to $270 million .FY 2016 earnings per share view $-1.10, revenue view $266.4 million -- Thomson Reuters I/B/E/S.  Full Article

Spectranetics Q2 loss per share $0.35
Thursday, 28 Jul 2016 04:01pm EDT 

Spectranetics Corp : FY2016 earnings per share view $-1.11, revenue view $262.7 million -- Thomson Reuters I/B/E/S . Reports second quarter 2016 revenue of $67.7 million . Sees FY 2016 non-GAAP loss per share $1.06 to $1.18 . Sees FY 2016 loss per share $1.37 to $1.49 . Q2 revenue $67.7 million versus i/b/e/s view $65 million . Q2 loss per share $0.35 . Sees FY 2016 revenue $258 million to $268 million .Q2 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.  Full Article

QT Vascular updates on ongoing litigation with AngioScore
Monday, 25 Jul 2016 01:12am EDT 

QT Vascular Ltd : QT Vascular announces federal circuit reversing adverse judgement . On 21 July, 3-judge panel of US court of appeals reversed district court judgement awarding angioscore more than US$20 million in damages . Federal circuit ordered the district court to dismiss the State law claims . Federal circuit held that district court erred as a matter of law when it exercised subject matter jurisdiction over state law claims .  Full Article

Spectranetics Corp reaffirms FY 2016 outlook
Thursday, 28 Apr 2016 04:00pm EDT 

Spectranetics Corp:reaffirms previously given FY 2016 outlook, as disclosed on February 25, 2016.Sees FY 2016 revenue is projected to be within a range of $254 million to $266 million.Sees Net loss for FY 2016 is projected to be within a range of $59 million to $64 million, or $1.34 to $1.45 per share.Sees Non-GAAP net loss for FY 2016 is projected to be within a range of $45 million to $50 million, or $1.03 to $1.14 per share.  Full Article

Spectranetics announces FDA Submission of Bridge Occlusion Balloon for Lead Extraction Procedures
Tuesday, 8 Dec 2015 06:49pm EST 

Spectranetics:Says U.S. Food and Drug Administration (FDA) Premarket Notification 510(k) submission of the Bridge Occlusion Balloon.  Full Article

Spectranetics Corp narrows FY 2015 revenue guidance; reaffirms FY 2015 earnings guidance
Thursday, 22 Oct 2015 04:01pm EDT 

Spectranetics Corp:Updates its projected FY 2015 revenue to be within a range of $242 million to $248 million compared with $240 million to $250 million previously projected.Projects FY 2015 Net loss to be within a range of $65.0 million to $69.0 million, or $1.53 to $1.62 per share, unchanged from previous projections.Projects FY 2015 Non-GAAP net loss to be within a range of $40.0 million to $44.0 million, or $0.94 to $1.04 per share, compared with previous projections of $41 million to $45 million, or $0.96 to $1.07 per share.FY 2015 revenue of $244 million and EPS of $(1.02) - Thomson Reuters I/B/E/S.  Full Article

Jury in Federal Court in California finds against Spectranetics Corp's wholly owned subsidiary AngioScore's patent infringement claims
Wednesday, 30 Sep 2015 09:01am EDT 

Spectranetics Corp:Says that a jury in the U.S. District Court for the Northern District of California has found against its wholly owned subsidiary, AngioScore Inc., plaintiff in lawsuit seeking damages and other relief for patent infringement.Says for patent infringement against defendants Eitan Konstantino, TriReme Medical, LLC, Quattro Vascular Pte Ltd. and QT Vascular Ltd. related to defendants' Chocolate PTA balloon catheter.Says jury also found that certain claims of the asserted patent are invalid.  Full Article

More From Around the Web

BRIEF-Spectranetics reports Q1 loss per share $0.43

* Spectranetics reports first quarter 2017 revenue of $69.7 million